A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 70 , 423–431 (2006). Article CAS Google Scholar ...

Atypical hemolytic uremic syndrome often progresses to end-stage renal disease and recurs after kidney transplantation, even with empiric plasma therapy. Guidelines on the treatment of this ...

Thirty-two-year-old Looney was diagnosed with end-stage kidney disease in May 2023 and atypical hemolytic uremic syndrome, or aHUS, in July. Nonetheless, the Springfield native, who has lived and ...

atypical hemolytic uremic syndrome and sickle cell disease. PNH is a rare and life-threatening blood condition wherein red blood cells are destroyed by the complement system – part of the innate ...

Medscape, April 29, 2024 Fast Five Quiz: aHUS Management How much do you know about atypical hemolytic uremic syndrome treatment and management? Test your knowledge with this quick quiz.

Your doctor will determine the best dosage to fit your needs. Dosage for atypical hemolytic uremic syndrome (aHUS) The dosage of Ultomiris IV infusion for aHUS is based on body weight in kilograms ...

paroxysmal nocturnal hemoglobinuria atypical hemolytic uremic syndrome. For this use, Ultomiris is given to help prevent blood clots and damage to the small blood vessels from occurring.

Treatments for uremic bleeding target the various factors that seem to have a role in platelet dysfunction. Interventions can exert acute (within 6 h) or delayed (within several weeks) effects ...

to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Post-acute respiratory complications were more common in COVID-19 patients in South Korea and Japan than in the ...

Its leading commercial drugs include Tagrisso for lung cancer, Farxiga for type 2 diabetes and Soliris for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Analyst ...

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life ...

While mutations in the C-terminal domains of FH are associated with atypical hemolytic uremic syndrome (aHUS) the Y402H polymorphism in domain 7 is associated with age-related macular degeneration ...